A detailed history of China Universal Asset Management Co., Ltd. transactions in Amgen Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 57,394 shares of AMGN stock, worth $17.8 Million. This represents 2.11% of its overall portfolio holdings.

Number of Shares
57,394
Previous 57,394 -0.0%
Holding current value
$17.8 Million
Previous $16.3 Million -0.0%
% of portfolio
2.11%
Previous 2.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$268.87 - $324.56 $6.86 Million - $8.28 Million
25,510 Added 80.01%
57,394 $16.3 Million
Q4 2023

May 21, 2024

SELL
$255.7 - $288.46 $6.52 Million - $7.36 Million
-25,510 Reduced 44.45%
31,884 $9.18 Million
Q4 2023

Jan 23, 2024

BUY
$255.7 - $288.46 $5.54 Million - $6.25 Million
21,667 Added 212.07%
31,884 $9.18 Million
Q3 2023

May 21, 2024

BUY
$218.65 - $271.46 $994,638 - $1.23 Million
4,549 Added 80.26%
10,217 $2.75 Million
Q3 2023

Oct 30, 2023

BUY
$218.65 - $271.46 $994,638 - $1.23 Million
4,549 Added 80.26%
10,217 $2.75 Million
Q2 2023

May 21, 2024

BUY
$214.27 - $253.37 $126,205 - $149,234
589 Added 11.6%
5,668 $1.26 Million
Q2 2023

Jul 27, 2023

BUY
$214.27 - $253.37 $126,205 - $149,234
589 Added 11.6%
5,668 $1.26 Million
Q1 2023

May 21, 2024

BUY
$225.79 - $275.2 $448,193 - $546,272
1,985 Added 64.16%
5,079 $1.23 Million
Q1 2023

Apr 27, 2023

BUY
$225.79 - $275.2 $448,193 - $546,272
1,985 Added 64.16%
5,079 $1.23 Million
Q4 2022

May 21, 2024

SELL
$229.03 - $291.01 $12.4 Million - $15.8 Million
-54,300 Reduced 94.61%
3,094 $812,000
Q4 2022

Jan 31, 2023

BUY
$229.03 - $291.01 $458 - $582
2 Added 0.06%
3,094 $813,000
Q3 2022

Oct 21, 2022

BUY
$224.46 - $253.15 $694,030 - $782,739
3,092 New
3,092 $697,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $165B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.